United Therapeutics Corporation Debt Securities, Available-for-sale, Amortized Cost
United Therapeutics Corporation (UTHR) had Debt Securities, Available-for-sale, Amortized Cost of $2.62 billion as of 2021-09-30, per its 10-Q filed 2021-11-03.
Discontinued › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2021-11-03
- 2021-09-30: Debt Securities, Available-for-sale, Amortized Cost $2.62B.
- 2021-06-30: Debt Securities, Available-for-sale, Amortized Cost $2.28B.
- 2021-03-31: Debt Securities, Available-for-sale, Amortized Cost $2.26B.
- 2020-12-31: Debt Securities, Available-for-sale, Amortized Cost $2.23B.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2021-09-30 | $2.62B 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $2.28B 10-Q · filed 2021-08-04 | |
| 2021-03-31 | $2.26B 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $2.23B 10-Q · filed 2021-11-03 | |
| 2020-09-30 | $2.10B 10-Q · filed 2020-10-28 | |
| 2020-06-30 | $1.83B 10-Q · filed 2020-07-29 | |
| 2020-03-31 | $1.50B 10-Q · filed 2020-04-29 | |
| 2019-12-31 | $1.45B 10-K · filed 2021-02-24 | |
| 2019-09-30 | $1.51B 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $1.26B 10-Q · filed 2019-07-31 | |
| 2019-03-31 | $1.22B 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $1.15B 10-K · filed 2020-02-26 | $1.15B 10-K · filed 2019-02-27 |
| 2018-09-30 | $1.14B 10-Q · filed 2018-10-31 | |
| 2018-06-30 | $1.08B 10-Q · filed 2018-08-01 | |
| 2018-03-31 | $720.50M 10-Q · filed 2018-05-02 | |
| 2017-12-31 | $740.40M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |